XORTX Therapeutics Inc (XRTX)

US · Healthcare · Biotechnology

$1.66-6.74%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.7M

EPS

$-1.05

Market cap

$4.2M

Forward P/E

1.0

P/B

0.76

Book value

$1.50

EPS (TTM)

$-2.58

52-week high

$7.05

52-week low

$1.73

50-day MA

$2.13

200-day MA

$2.39

Beta

0.44

Analysts rate XORTX Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $14.04.

Insiders

7.83%

Institutions

4.19%

Fund	Stake
Citadel Advisors Llc	1.27%
Kingsview Wealth Management, LLC	0.83%
Hartland & Co	0.02%
NATIONAL BANK OF CANADA /FI/	0.01%
DRW Securities, LLC	0.00%
Royal Bank of Canada	0.00%
Baader Bank INC	0.00%
TWO SIGMA SECURITIES, LLC	0.00%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for XORTX Therapeutics Inc — free to start.

Data updated 2026-09-18.